Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment

Journal of B.U.ON.

Volumn 19, Issue 4, 2014, Pages 965-972

  Ding, Shan Shan ^a   Li, Li ^a   Yu, Chun Xia ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Bevacizumab; Efficacy; Randomized controlled trials; Recurrent ovarian cancer; Systematic evaluation

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ABSCESS; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; EVALUATION STUDY; FEMALE; FISTULA; HEART DISEASE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MEDLINE; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOEMBOLISM; DISEASE FREE SURVIVAL; NEOPLASM; OVARY TUMOR;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84921925914     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Siegel R, Naishadham MA, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 2008;67:103-112.
3. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2012;8:CD005343.
4. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7:20-28.
5. Parazzini F, Raspagliesi F, Guarnerio P, Bolis G. Role of secondary surgery in relapsed ovarian cancer. Crit Rev Oncol Hematol 2001;37:121-125.
6. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25:2894-2901.
7. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-5171.
8. Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007;107:326-330.
9. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
10. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia. Gynecol Oncol 2008;110:49-55.
11. Higgins JPT, Green S (Eds). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. 2011.
12. Higgins JR, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
13. Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;18:LBA5002.
14. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a Randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-2045.
15. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009;374:1371-1382.
16. Stuart GC, Kitchener H, Bacon M et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21:750-755.
17. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728.
18. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72-84.
19. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
20. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-680.
21. Kamba T, Tarn BY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-576.
22. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.